Pfizer Inc.

NYSE:PFE   12:07:01 PM EDT
-0.04 (-0.07%)
Earnings Announcements, Mergers / Acquisitions

Pfizer To Acquire Biohaven Pharmaceuticals

Published: 05/10/2022 11:04 GMT
Pfizer Inc. (PFE) - Pfizer to Acquire Biohaven Pharmaceuticals.
Pfizer Inc - Pfizer Will Pay Transaction Consideration Totaling Approximately $11.6 Billion in Cash.
Pfizer Inc - Biohaven Common Shareholders Will Receive $148.50 per Biohaven Share in Cash.
Pfizer Inc - Pfizer Expects to Finance Transaction With Existing Cash on Hand.
Pfizer Inc - Biohaven Shareholders Will Receive Plus 0.5 of a Share of New Publicly Traded Company That Retains Biohaven's Non-cgrp Pipeline Compounds.
Pfizer Inc - Co Will Make Payments to Settle Biohaven's Third Party Debt and for Redemption of All Outstanding Shares of Redeemable Preferred Stock.
Pfizer Inc - Biohaven Will Not Hold a Conference Call to Discuss Its Q1 2022 Financial Results.
Pfizer Inc - Pfizer's Acquisition of Biohaven is Subject to Completion of New Biohaven Spin-off Transaction.
Pfizer - New Biohaven to Have Right to Get Tiered Royalties From Co on Any Annual Net Sales of Rimegepant & Zavegepant in U.S. in Excess of $5.25 Billion.
Revenue is expected to be $26.02 Billion
Adjusted EPS is expected to be $1.81

Next Quarter Revenue Guidance is expected to be $25.94 Billion
Next Quarter EPS Guidance is expected to be $1.88

More details on our Analysts Page.